期刊文献+

晚期转移性乳腺癌内分泌治疗进展 被引量:2

原文传递
导出
摘要 晚期转移性乳腺癌患者由于体质差 ,对二次手术和化疗一般不能耐受。内分泌治疗由于副作用小 ,缓解率高 ,为广大医患所接受 ,特别是雌激素受体 (ER)或孕激素受体 (PR)阳性的患者 ,其治疗效果甚至优于化疗。由于雌激素来源的不同 ,绝经前后内分泌治疗药物选择有所不同。
出处 《国际肿瘤学杂志》 CAS 2005年第1期47-50,共4页 Journal of International Oncology
关键词 乳腺肿瘤 治疗
  • 相关文献

参考文献23

  • 1BuzdarA,DoumaJ,DavidsonN ,etal.PhaseⅢ,multicenter,double blind,randomizedstudyofletrozole,anaromatasein hibitor,foradvancedbreastcancerversusmegestrolacetate. JClinOncol . 2001
  • 2MouridsenH,GershanovichM,SunY ,etal.PhaseЩstudyofletrozoleversustamoxifenasfirst linetherapyofadvancedbreastcancerinpostmenopausalwomen:analysisofsurvivalandupdateofefficiencyfromtheInternationalLetrozoleBreastCancerGroup. JClinOncol . 2003
  • 3ThurlimannB,HessD,KoberleD ,etal.Anastrozole (′Arim idex′)versustamoxifenasfirst linetherapyin postmenopausalwomenwithadvancedbreastcancer:resultsofthedouble blindcross overSAKKtrial21/95 asub studyoftheTARGET (Ta moxifenor′Arimidex′RandomizedGroupEfficacyandTolerabili ty)trial. Breast Cancer Research and Treatment . 2004
  • 4ParidaensR,DirixL,LohrischC ,etal.Matureresultsofaran domizedphaseⅡmulticenterstudyofexemestaneversustamoxifenasfirst linehormonetherapyfor postmenopausalwomenwithmetastaticbreastcancer. Annals of Oncology . 2003
  • 5LonningPE,BajettaE,MurrayR ,etal.Activityofexemestaneinmetastaticbreastcancerafterfailureofnonsteroidalaromatasein hibitor:aphaseⅡtrial. JClinOncol . 2000
  • 6Forward DP,Cheung KL,Jackson L,et al.Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. British Journal of Cancer . 2004
  • 7Bonneterre J,Buzdar A,Nabholtz JM,et al.Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer . 2001
  • 8Port ER,Montgomery LL,Heerdt AS,et al.Patient reluctance toward tamoxifen use for breast cancer primary prevention. Annals of Surgical Oncology . 2001
  • 9Boccardo F,Rubagotti A,Amoroso D,et al.Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. Journal of Clinical Oncology . 2001
  • 10RoseC.A comparison of the efficacy of aromatase inhibitors in secondline treatment of metastatic breast cancer. American Journal of Clinical Oncology . 2003

同被引文献43

  • 1俞亚静.三苯氧胺在乳腺癌病人中的应用[J].安徽医药,2005,9(8):628-629. 被引量:8
  • 2Hamilton A, piccart M. The third - generation non - steroidal aromatase inhibitors : a review of their clinical benefits in the second - line hormonal treatment of advanced breast cancer [J]. Anals of Oncology, 1999,10 (4) :377 - 384.
  • 3Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer:an overview of the randomized trials [J].Lancet, 1998. 351 : 1451.
  • 4江泽飞,宋三泰.乳腺癌的内分泌治疗[A].韩锐,孙燕.新世纪癌的化学预防与药物治疗[M].北京:人民军医出版社,2005:840.
  • 5Lonning PE. Clinico - pharmacilogical aspects of different hormone treatment[J]. Eur J Cancer,2000,36( suppl 4) :81 -82.
  • 6Howell A. Faslodex ( ICI 182780), an oestragen receptor downregulator [ J ]. Eur J Cancer,2000,36 ( suppl 4 ) : 87 - 88.
  • 7Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women [ J ]. Oncologist ,2004,9 (2) : 126 - 136.
  • 8Howell A, Cuzick J, Baum M, et al. Results of the ATAC ( Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years'adjuvant treatment for breast cancer[ J]. Lancet,2005, 365:60 -62.
  • 9Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine - responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen : combined results of ABCSG Trial 8 and ARNO 95 Trial[J]. Lancet,2005,366 (9484) :455 - 462.
  • 10Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer[ J]. N Engl J Med ,2005,353 (26) :2747 -2757.

引证文献2

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部